

BIOGRAPHICAL SKETCH

Name [Last, First, Middle Initial(s), Degree(s)]

Cavalla Paola, MD

Position/Title:

Consultant Neurologist

Education

[Begin with baccalaureate or other professional education and include postdoctoral training]

Institution and Location	Degree	Year Conferred	Field of Study
University of Turin	MD	1991	Research Thesis on neuropathology "Neoplastic transformation and reactive glia: an experimental study "
University of Turin	Neurologist	1995	Research Thesis on "Significance of programmed cell death (apoptosis) in neurological diseases"

Research and Professional Experience

[List in chronological order, previous employment, experience and honors]

1991-1995: Resident in Neurology at University of Turin

2002-to date: Teacher in the Degree Course in Techniques of Biomedical Laboratory", with the course "Molecular, cellular and tissue Physiology"

1997 to date: 1[^] Level Medical Manager as Consultant Neurologist at " Health and Science City University Hospital of Turin", Turin (previously "San Giovanni Battista University Hospital", Turin).

1999 to date: Principal Investigator in several phase II and III clinical trials on Multiple Sclerosis.

2004-to date: Member of PROGEMUS network (PRognostic Genetic Factors in Multiple Sclerosis) coordinated by Prof. S. D'Alfonso and M. Leone, that has promoted a multicenter observational study on more than 2000 patients in 11 MS centers, collecting biological data together with clinical and response to therapy data. As a member of the PROGEMUS network, participation to the studies of the International Multiple Sclerosis Genetic Consortium (IMSGC).

2008-2009: Coordinator of the project "Multiple Sclerosis, heteroneneous or homogeneous pathogenesis? Identification of immunopathogenic mechanisms for a focused therapy." funded by Ricerca Sanitaria Finalizzata, Piedmont Region.

2009 -2011: Participation in the research group for the project "Role of Progranulin in Multiple Sclerosis", funded by FISM (Fondazione Italiana Sclerosi Multipla) in 2009.

2006 to date: Coordinator of the research group for the neuropathological study "Pathology of grey matter in Multiple Sclerosis" in collaboration with Division of Neurology, University of Genoa.

2014-2016: Teacher of Neurology (Med 26, in the 3rd year - common path), Residency School in Neurology, Department of Neuroscience, University of Turin

2016: Teacher of "Approach to Multiple Sclerosis: Physiopathology and Clinic" in the module 6 of the "Master in Nursing in Neuroscience", Department of Neuroscience, University of Turin

Publications

- 1 p27/kip1 expression in oligodendrogliomas and its possible prognostic role. **Cavalla P**, Piva R, Bortolotto S, Grosso R, Cancelli I, Chiò A, Schiffer D Acta Neuropathol 98:629-634, 1999
- 2 Grey matter pathology in multiple sclerosis. Vercellino M, Plano F, Votta B, Mutani R, Giordana MT, **Cavalla P**. J Neuropathol Exp Neurol, 2005;64:1101-7.
- 3 Fertility in patients with multiple sclerosis: current knowledge and future perspectives. **P Cavalla**, V Rovei, S. Masera, M Vercellino, M Massobrio, R Mutani, A. Revelli. Neurol Sci 27:231-239, 2006
- 4 Altered glutamate reuptake in RR and SP multiple sclerosis cortex: correlation with microglia infiltration, demyelination, neuronal and synaptic damage. Vercellino M, Merola A, **Cavalla P**. J Neuropathol Exp Neurol 66: 732-739, 2007
- 5 Involvement of the choroid plexus in multiple sclerosis autoimmune inflammation: a neuropathological study. Vercellino M, Votta B, Condello C, Piacentino C, Romagnolo A, Merola A, Capello E, Mancardi GL, Mutani R, Giordana MT, **Cavalla P**. J Neuroimmunol. 2008;199(1-2):133-41
- 6 Real-life impact of early interferon beta therapy in relapsing multiple sclerosis. Trojano M, Pellegrini F, Paolicelli D, Fuiani A, Zimatore GB, Tortorella C, Simone IL, Patti F, Ghezzi A, Zipoli V, Rossi P, Pozzilli C, Salemi G, Lugaresi A, Bergamaschi R, Millefiorini E, Clerico M, Lus G, Vianello M, Avolio C, **Cavalla P**, Lepore V, Livrea P, Comi G, Amato MP; Italian Multiple Sclerosis Database Network (MSDN) Group. Ann Neurol. 2009;66(4):513-20
- 7 Multiple sclerosis relapses: a multivariable analysis of residual disability determinants. Vercellino M, Romagnolo A, Mattioda A, Masera S, Piacentino C, Merola A, Chiò A, Mutani R, **Cavalla P**. Acta Neurol Scand. 2009;119:126-30.
- 8 Demyelination, inflammation, and neurodegeneration in multiple sclerosis deep gray matter. Vercellino M, Masera S, Lorenzatti M, Condello C, Merola A, Mattioda A, Tribolo A, Capello E, Mancardi GL, Mutani R, Giordana MT, **Cavalla P**. J Neuropathol Exp Neurol. 2009;68(5):489-502
- 9 Progranulin expression in brain tissue and cerebrospinal fluid levels in multiple sclerosis. Vercellino M, Grifoni S, Romagnolo A, Masera S, Mattioda A, Trebini C, Chiavazza C, Caligiana L, Capello E, Mancardi GL, Giobbe D, Mutani R, Giordana MT, **Cavalla P**. Mult Scler. 2011;17(10):1194-201
- 10 Duloxetine is effective in treating depression in multiple sclerosis patients: an open-label multicenter study. Solaro C, Bergamaschi R, Rezzani C, Mueller M, Trabucco E, Bargiggia V, Dematteis F, Mattioda A, Cimino V, Restivo D, Patti F, **Cavalla P**. Clin Neuropharmacol. 2013;36:114-6
- 11 No evidence for a role of rare CYP27B1 functional variations in multiple sclerosis. Barizzzone N, Pauwels I, Luciano B, Franckaert D, Guerini FR, Cosemans L, Hilven K, Salvati A, Dooley J, Danso-Abeam D, di Sapio A, **Cavalla P**, Decallonne B, Mathieu C, Liston A, Leone M, Dubois B, D'Alfonso S, Goris A. Ann Neurol. 2013 Mar;73(3):433-7
- 12 Atypical hereditary spastic paraplegia mimicking multiple sclerosis associated with a novel SPG11 mutation. Romagnolo A, Masera S, Mattioda A, Superti G, Santorelli FM, Mongini T, Pinessi L, **Cavalla P**. Eur J Neurol. 2014 Feb;21(2):e14-5
- 13 Fingolimod versus interferon beta/glatiramer acetate after natalizumab suspension in multiple sclerosis. Iaffaldano P, Lucisano G, Pozzilli C, Brescia Morra V, Ghezzi A, Millefiorini E, Patti F, Lugaresi A, Zimatore GB, Marrosu MG, Amato MP, Bertolotto A, Bergamaschi R, Granella F, Coniglio G, Tedeschi G, Sola P, Lus G, Ferrò MT, Iuliano G, Corea F, Protti A, **Cavalla P**, Guareschi A, Rodegher M, Paolicelli D, Tortorella C, Lepore V, Prosperini L, Saccà F, Baroncini D, Comi G, Trojano M; Italian iMed-Web database. Brain. 2015 Nov;138(Pt 11):3275-86
- 14 Parity is associated with a longer time to reach irreversible disability milestones in women with multiple sclerosis. Masera S, **Cavalla P**, Prosperini L, Mattioda A, Mancinelli CR, Superti G, Chiavazza C, Vercellino M, Pinessi L, Pozzilli C. Mult Scler. 2015 Sep;21(10):1291-7
- 15 Progranulin genetic polymorphisms influence progression of disability and relapse recovery in multiple sclerosis. Vercellino M, Fenoglio C, Galimberti D, Mattioda A, Chiavazza C, Binello E, Pinessi L, Giobbe D, Scarpini E, **Cavalla P**. Mult Scler. 2016 Jul;22(8):1007-12
- 16 Rituximab suppresses disease activity after natalizumab withdrawal: an exploratory study. S. Malucchi, M. Capobianco, A. di Sapio, M. Lo Re, **P. Cavalla**, A. Bertolotto. Multiple Sclerosis and Demyelinating Disorders (2016) 1:11

Firma
